Enveric Licenses RCANN Trademarks to TOTEC, Signals Asset Monetization
Event summary
- Enveric Biosciences’ subsidiary, Akos Biosciences, licensed its US Trademark portfolio for RCANN™ to TOTEC Pharma.
- TOTEC, an affiliate of Aries Science & Technology, is advancing the commercialization of cannabinoid crème technology originally developed by Enveric.
- The trademark license includes an option for TOTEC to purchase the RCANN trademark portfolio based on future development and commercialization milestones.
- The deal is intended to enhance the value of the previously licensed cannabinoid technology and support Enveric’s business development strategy.
The big picture
This trademark license and option agreement signals Enveric’s ongoing strategy of monetizing non-core assets to fund its primary focus on neuroplastogenic therapeutics. The deal with TOTEC, backed by Aries, highlights the growing interest in cannabinoid-based topical treatments, particularly for dermatological conditions like radiation dermatitis, a market with significant unmet need. The option structure suggests Enveric is seeking to retain upside potential while mitigating risk associated with TOTEC’s commercialization efforts.
What we're watching
- Milestone Risk
- The option to purchase the trademark portfolio is contingent on TOTEC achieving specific milestones, creating uncertainty around Enveric’s potential future revenue from the deal.
- Commercialization
- The success of TOTEC’s commercialization efforts for the cannabinoid crème will be critical in determining the overall value of the arrangement and potential royalties for Enveric.
- Asset Strategy
- Enveric’s continued focus on out-licensing non-core assets suggests a broader strategic shift towards concentrating resources on its neuroplastogenic therapeutics pipeline.
Related topics